Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) COO Jonathan Yen-Wen Yu sold 300 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $82.53, for a total value of $24,759.00. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at $4,483,359.72. The trade was a 0.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Jonathan Yen-Wen Yu also recently made the following trade(s):
- On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52.
- On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56.
- On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total value of $8,250.00.
- On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
- On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
- On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.
Disc Medicine Trading Up 0.3%
IRON stock traded up $0.26 during midday trading on Wednesday, reaching $82.67. The company’s stock had a trading volume of 586,890 shares, compared to its average volume of 329,310. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The firm has a market capitalization of $316.63 million, a price-to-earnings ratio of -12.56 and a beta of 1.00. The stock has a fifty day simple moving average of $76.56 and a two-hundred day simple moving average of $69.95. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on IRON shares. Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 target price on shares of Disc Medicine in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. HC Wainwright increased their price target on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $106.50.
Get Our Latest Analysis on IRON
Institutional Investors Weigh In On Disc Medicine
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Disc Medicine by 22.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares in the last quarter. Millennium Management LLC increased its position in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after buying an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after buying an additional 3,454 shares in the last quarter. Legal & General Group Plc raised its stake in Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after buying an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Disc Medicine by 21.6% in the second quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after buying an additional 2,983 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.
Disc Medicine Company Profile
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Articles
- Five stocks we like better than Disc Medicine
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
